JP2018521664A - タウリン補足細胞培養培地およびその使用 - Google Patents

タウリン補足細胞培養培地およびその使用 Download PDF

Info

Publication number
JP2018521664A
JP2018521664A JP2018503655A JP2018503655A JP2018521664A JP 2018521664 A JP2018521664 A JP 2018521664A JP 2018503655 A JP2018503655 A JP 2018503655A JP 2018503655 A JP2018503655 A JP 2018503655A JP 2018521664 A JP2018521664 A JP 2018521664A
Authority
JP
Japan
Prior art keywords
antibody
protein
taurine
cell culture
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018503655A
Other languages
English (en)
Japanese (ja)
Inventor
エイミー エス． ジョンソン，
エイミー エス． ジョンソン，
メーガン イー． ケイシー，
メーガン イー． ケイシー，
シャディア オショディ，
シャディア オショディ，
ショーン ローレンス，
ショーン ローレンス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56738219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2018521664(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2018521664A publication Critical patent/JP2018521664A/ja
Priority to JP2021080955A priority Critical patent/JP7198868B2/ja
Priority to JP2022135752A priority patent/JP7495451B2/ja
Priority to JP2024084163A priority patent/JP7781954B2/ja
Priority to JP2024084162A priority patent/JP7850767B2/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/74—Undefined extracts from fungi, e.g. yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2018503655A 2015-08-04 2016-08-03 タウリン補足細胞培養培地およびその使用 Withdrawn JP2018521664A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2021080955A JP7198868B2 (ja) 2015-08-04 2021-05-12 タウリン補足細胞培養培地およびその使用
JP2022135752A JP7495451B2 (ja) 2015-08-04 2022-08-29 タウリン補足細胞培養培地およびその使用
JP2024084163A JP7781954B2 (ja) 2015-08-04 2024-05-23 タウリン補足細胞培養培地およびその使用
JP2024084162A JP7850767B2 (ja) 2015-08-04 2024-05-23 タウリン補足細胞培養培地およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200689P 2015-08-04 2015-08-04
US62/200,689 2015-08-04
PCT/US2016/045403 WO2017024062A1 (en) 2015-08-04 2016-08-03 Taurine supplemented cell culture medium and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021080955A Division JP7198868B2 (ja) 2015-08-04 2021-05-12 タウリン補足細胞培養培地およびその使用

Publications (1)

Publication Number Publication Date
JP2018521664A true JP2018521664A (ja) 2018-08-09

Family

ID=56738219

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018503655A Withdrawn JP2018521664A (ja) 2015-08-04 2016-08-03 タウリン補足細胞培養培地およびその使用
JP2021080955A Active JP7198868B2 (ja) 2015-08-04 2021-05-12 タウリン補足細胞培養培地およびその使用
JP2022135752A Active JP7495451B2 (ja) 2015-08-04 2022-08-29 タウリン補足細胞培養培地およびその使用
JP2024084163A Active JP7781954B2 (ja) 2015-08-04 2024-05-23 タウリン補足細胞培養培地およびその使用
JP2024084162A Active JP7850767B2 (ja) 2015-08-04 2024-05-23 タウリン補足細胞培養培地およびその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2021080955A Active JP7198868B2 (ja) 2015-08-04 2021-05-12 タウリン補足細胞培養培地およびその使用
JP2022135752A Active JP7495451B2 (ja) 2015-08-04 2022-08-29 タウリン補足細胞培養培地およびその使用
JP2024084163A Active JP7781954B2 (ja) 2015-08-04 2024-05-23 タウリン補足細胞培養培地およびその使用
JP2024084162A Active JP7850767B2 (ja) 2015-08-04 2024-05-23 タウリン補足細胞培養培地およびその使用

Country Status (16)

Country Link
US (8) US11312936B2 (enExample)
EP (3) EP4442808A3 (enExample)
JP (5) JP2018521664A (enExample)
KR (3) KR20240144463A (enExample)
CN (2) CN107922920B (enExample)
AR (3) AR105602A1 (enExample)
AU (4) AU2016301305B2 (enExample)
BR (1) BR112018002214A2 (enExample)
CA (3) CA3236085A1 (enExample)
EA (1) EA201890137A1 (enExample)
HK (1) HK1248279A1 (enExample)
IL (5) IL313856B2 (enExample)
MX (2) MX390940B (enExample)
MY (3) MY208943A (enExample)
TW (5) TWI870789B (enExample)
WO (1) WO2017024062A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506413A (ja) * 2018-11-02 2022-01-17 ウーシー バイオロジクス アイルランド リミテッド 連続的採取を行い細胞流出を行わない強化灌流による細胞培養法
JP2022512928A (ja) * 2018-11-07 2022-02-07 リヒター ゲデオン ニュイルヴァーノシャン ミューコェデー レースヴェーニュタールシャシャーグ 細胞培養で生産される組換え糖タンパク質のグリコシル化プロファイルを変更する方法
JP7855505B2 (ja) 2019-12-06 2026-05-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TWI870789B (zh) * 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
BR112020000127A2 (pt) * 2017-07-06 2020-07-07 Regeneron Pharmaceuticals, Inc. método para selecionar um hidrolisado de soja, e, glicoproteína
CN108918892B (zh) * 2018-08-01 2021-04-27 百奥泰生物制药股份有限公司 一种测定抗vegf抗体活性的方法及其应用
EP3911731A1 (en) * 2019-01-17 2021-11-24 Boehringer Ingelheim Animal Health USA Inc. Serum-free medium for avian vaccine production and uses thereof
CN109777793B (zh) * 2019-03-15 2020-12-08 常熟理工学院 一种gdsl脂肪酶、基因工程菌及其应用
US10961500B1 (en) * 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
US20220204920A1 (en) * 2019-05-16 2022-06-30 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
KR20220093196A (ko) * 2019-11-04 2022-07-05 루비우스 테라퓨틱스, 아이엔씨. 타우린 또는 하이포타우린을 사용하여 제핵 적혈구 세포를 생성하는 방법
CN110862972B (zh) * 2019-11-07 2020-10-30 衡阳师范学院 一种犬腺病毒ⅰ型无血清培养方法
CN113005082B (zh) * 2019-12-20 2023-08-18 苏州依科赛生物科技股份有限公司 一种t细胞无血清培养基及其应用
CN113025590B (zh) * 2019-12-24 2022-08-09 华熙生物科技股份有限公司 一种提高环糊精葡萄糖基转移酶分泌表达的优化方法及其应用
KR20230002642A (ko) * 2020-04-15 2023-01-05 제넨테크, 인크. 접종 전 배지를 처리하는 방법
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
KR102296986B1 (ko) * 2021-01-21 2021-08-31 정덕수 우태아혈청 성분의 유해함을 극복하기 위한 화학적으로 정의된 줄기세포배양액 개발
WO2023278631A1 (en) * 2021-06-29 2023-01-05 Tega Therapeutics, Inc. Heparin from modified mst cells and methods of making and using
CN113480652B (zh) * 2021-07-30 2023-04-07 成都景泽生物制药有限公司 一种重组cho细胞发酵培养生产重组egfr抗体活性分子的方法
KR20230080056A (ko) 2021-11-29 2023-06-07 (주)아모레퍼시픽 릴린 및/또는 vegf-c의 생산 및/또는 활성 촉진제 및 이를 이용한 피부 외용제
JP2025507790A (ja) * 2022-03-02 2025-03-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高力価抗体のための製造プロセス
CN115029313B (zh) * 2022-08-12 2022-11-01 依科赛生物科技（太仓）有限公司 一种用于t细胞培养基的氨基酸组合物
CN118240744B (zh) * 2024-03-06 2024-11-26 上海迈邦生物科技有限公司 一种同时调节细胞表达产物聚体、电荷异质性和提高产量的方法
WO2025199245A1 (en) * 2024-03-19 2025-09-25 Immunis, Inc. Method of making and using secretome composition
CN118697740A (zh) * 2024-06-27 2024-09-27 华中科技大学同济医学院附属协和医院 次黄嘌呤在抗肿瘤免疫治疗中的应用
CN121610451B (zh) * 2026-02-02 2026-04-21 重庆天怡美生命科学有限公司 一种含有次牛磺酸的nk培养基及其在提高nk细胞增殖和杀伤活性中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517235A (ja) * 1998-06-08 2002-06-18 ジェネスパン コーポレイション 安定化一過性遺伝子発現
CN101603026A (zh) * 2009-06-19 2009-12-16 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
US3883511A (en) 1974-03-07 1975-05-13 Rit Rech Ind Therapeut New 6-aminopenicillanic acid derivative
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DE3271210D1 (en) 1981-12-24 1986-06-19 Asahi Chemical Ind Method for the cultivation of normal diploid cells and cultivation medium used therefor
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
DE3801236A1 (de) 1988-01-18 1989-07-27 Boehringer Mannheim Gmbh Pentosansulfat-medium
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5529920A (en) 1988-12-14 1996-06-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human liver epithelial cell line and culture media therefor
EP0449950A4 (en) 1988-12-14 1991-10-16 Us Health Cell culture medium for human liver epithelial cell line
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
JP2897043B2 (ja) * 1989-12-21 1999-05-31 東ソー株式会社 完全合成培地
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
JP3230091B2 (ja) 1990-06-25 2001-11-19 ウェルファイド株式会社 ヒト血清アルブミンの着色抑制方法
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1992009298A1 (en) 1990-11-23 1992-06-11 Peptide Technology Ltd. The delay, prevention and/or reversal of cell senescence
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
CA2131444A1 (en) 1992-03-04 1993-09-16 Kelli E. Smith Dna encoding taurine and gaba transporters and uses thereof
JPH07102147B2 (ja) 1992-03-16 1995-11-08 株式会社ミドリ十字 ヒト血清アルブミンの着色抑制方法
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5426699A (en) 1993-10-25 1995-06-20 Antec Corporation Method and apparatus for digitizing a scrambled analog video signal
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
CZ75597A3 (en) 1995-07-17 1997-08-13 Fraunhofer Ges Forschung Biologically active, metal containing ribonucleotide polypeptide, process of its preparation and pharmaceutical composition containing thereof
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6043092A (en) 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1998059035A2 (en) 1997-06-25 1998-12-30 The Goverment Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health Serum-free cell growth medium
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
CA2318376A1 (en) * 1998-01-12 1999-07-15 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6221665B1 (en) * 1998-06-10 2001-04-24 University Of South Florida Electrofusion chamber
AU754808B2 (en) 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
US6589759B1 (en) 1999-03-30 2003-07-08 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
MXPA01012630A (es) 1999-06-08 2002-07-22 Regeneron Pharma Polipeptidos quimericos modificados con propiedades farmacocineticas mejoradas.
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CN1114619C (zh) 1999-06-25 2003-07-16 中国科学院上海细胞生物学研究所 小鼠杂交瘤株Hepama－1分泌的肝癌鼠源单克隆抗体的制备方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
RU2192884C2 (ru) 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
WO2002057423A2 (en) 2001-01-16 2002-07-25 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
JP2005519580A (ja) 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 非ヒト動物由来のヒト抗肺炎球菌抗体
WO2002101019A2 (en) 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
IL160358A0 (en) 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
EP1321515A1 (en) 2001-12-21 2003-06-25 Ingenium Pharmaceuticals AG Method of culturing cells
CN1180080C (zh) 2002-01-18 2004-12-15 中国科学院上海细胞生物学研究所 一种改进的肝癌鼠源单克隆抗体的制备方法
US6927004B2 (en) 2002-03-08 2005-08-09 Asml Netherlands B.V. Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
US20030190710A1 (en) * 2002-03-28 2003-10-09 Devries Ruth L. Control of glycoforms in IgG
AU2003237259B2 (en) 2002-05-29 2008-01-24 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US7371922B2 (en) 2002-07-31 2008-05-13 The Board Of Trustees Of The University Of Illinois Nuclear transfer with porcine embryonic stem cells
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
AU2004205898B2 (en) 2003-01-17 2009-11-19 The Research Foundation Of State University Of New York Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
WO2004069172A2 (en) 2003-01-30 2004-08-19 The Government of the United States of America as represented by the Department of Veterans Affairs Multilineage-inducible cells and uses thereof
US7429491B2 (en) 2003-05-15 2008-09-30 Wyeth Restricted glucose feed for animal cell culture
CA2526398C (en) 2003-05-21 2014-07-15 Medarex, Inc. Human monoclonal antibodies against bacillus anthracis protective antigen
WO2005010160A2 (en) 2003-07-17 2005-02-03 Wisconsin Alumni Research Foundation Liquid crystals with reduced toxicity and applications thereof
EP1664283A4 (en) 2003-09-18 2007-12-26 Raven Biotechnologies Inc CELL CULTURE MEDIA
PL1767546T3 (pl) 2004-06-08 2012-07-31 Chengdu Kanghong Biotechnologies Co Ltd Hamujące angiogenezę białka chimeryczne i ich zastosowanie
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006050050A2 (en) * 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
US8273553B2 (en) 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
EP1848745B1 (en) 2005-02-18 2014-07-09 Medarex, L.L.C. Monoclonal antibodies against cd30 lacking in fucosyl residues
CA2605928A1 (en) 2005-04-21 2006-11-02 Glenn A. Goldstein N-acetylcysteine amide (nac amide) for treatment of oxidative stress associated with infertility
WO2006116369A2 (en) 2005-04-22 2006-11-02 Genentech, Inc. Method for treating dementia or alzheimer's disease with a cd20 antibody
DE102005046225B4 (de) * 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
AR058140A1 (es) 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
SI2522717T1 (sl) 2006-01-04 2014-05-30 Baxter International Inc. Mediji celične kulture brez oligopeptidov
DE602007008627D1 (de) 2006-02-14 2010-10-07 Genetix Ltd Zellkulturmedium
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN101421411B (zh) 2006-04-13 2015-06-03 中外制药株式会社 牛磺酸转运蛋白基因
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2007146123A2 (en) 2006-06-09 2007-12-21 Anthrogenesis Corporation Placental niche and use thereof to culture stem cells
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
LT2769992T (lt) * 2006-10-02 2021-04-12 Regeneron Pharmaceuticals, Inc. Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
CA2668771C (en) 2006-11-08 2016-03-15 Wyeth Rationally designed media for cell culture
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
BRPI0813985B1 (pt) 2007-07-31 2022-05-10 Regeneron Pharmaceuticals, Inc Anticorpos humanos ou fragmentos de ligação a antígenos, composição farmacêutica dos mesmos e método para produzir um anticorpo anti-cd20 humana ou fragmento de ligação a antígeno de um anticorpo
ES2591284T3 (es) 2007-08-07 2016-11-25 Chugai Seiyaku Kabushiki Kaisha Método para la producción de proteínas heterogéneas
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
CN100482786C (zh) 2007-12-28 2009-04-29 天津百若克医药生物技术有限责任公司 一种人胚肾293细胞扩增无蛋白培养基
DK2250251T3 (en) 2008-01-09 2018-01-22 Sartorius Stedim Cellca Gmbh Improved culture medium additive and method of using it
EP2342318A1 (en) 2008-09-26 2011-07-13 Schering Corporation High titer antibody production
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
EP2453874A2 (en) 2009-07-14 2012-05-23 Biogen Idec MA Inc. Methods for inhibiting yellow color and peroxide formation in a composition
KR101574056B1 (ko) 2009-07-31 2015-12-02 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US9045536B2 (en) 2009-12-23 2015-06-02 Merck Sharp & Dohme Corp. Cell line 3M
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
PT3626736T (pt) 2010-07-08 2025-08-11 Takeda Pharmaceuticals Co Método de produção de fvw recombinante de elevado peso molecular na cultura celular
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
EP2611904A2 (en) 2010-08-31 2013-07-10 Friesland Brands B.V. Culture medium for eukaryotic cells
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
EP2635905A2 (en) 2010-11-05 2013-09-11 AbbVie Inc. Efficient and effective supplement screening for the development of chemically defined media in cell culture
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
CN102093978A (zh) 2010-12-17 2011-06-15 上海市农业科学院 猪早期胚胎发育前期培养液及后期培养液
MY163081A (en) 2010-12-28 2017-08-15 Chugai Pharmaceutical Co Ltd Animal cell culturing method
WO2012092458A2 (en) 2010-12-30 2012-07-05 Anthrogenesis Corporation Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
EP2697361A1 (en) 2011-04-11 2014-02-19 Cellcura Asa Protein-free culture media products for manufacturing viral-based vaccines
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
WO2013063510A1 (en) * 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
JP6177249B2 (ja) 2011-11-14 2017-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
JP6090735B2 (ja) 2012-03-02 2017-03-08 国立大学法人山口大学 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
CA2875294C (en) 2012-04-25 2021-06-08 Riken Cell preparation containing myocardium-committed cell
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
ES2688019T3 (es) 2012-06-05 2018-10-30 The Regents Of The University Of California Métodos y composiciones para la producción acelerada de células epiteliales pigmentadas retinianas a partir de células pluripotentes
MX386767B (es) 2012-06-21 2025-03-19 Takeda Pharmaceuticals Co Filtración de virus de medio de cultivo celular.
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
CA2888281A1 (en) 2012-08-02 2014-02-06 Sanofi Article of manufacture comprising aflibercept or ziv-aflibercept
EP2882778B1 (en) 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
CN204634080U (zh) 2012-08-20 2015-09-09 施雷德公司 将led光源与电浪涌隔离的系统以及包括该系统的光源
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2921554B1 (en) * 2012-10-10 2019-12-04 Chugai Seiyaku Kabushiki Kaisha Method for establishing modified host cell
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
US9173380B2 (en) 2013-02-18 2015-11-03 Garmin Switzerland Gmbh Animal indicator apparatus
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
WO2014145098A1 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
KR20150127591A (ko) 2013-03-15 2015-11-17 리제너론 파아마슈티컬스, 인크. Il-33 길항제 및 이의 용도
US20160237400A1 (en) 2013-03-15 2016-08-18 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
JP6594860B2 (ja) 2013-05-29 2019-10-23 エフ．ホフマン−ラ ロシュ アーゲー シアル酸付加の定量的調節
JP6108170B2 (ja) * 2013-07-30 2017-04-05 株式会社大阪ソーダ 細胞培養用培地
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015063180A1 (en) * 2013-10-29 2015-05-07 Novozymes Biopharma Dk A/S Antibody composition
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
MX376230B (es) 2014-01-13 2025-03-07 Amgen Inc Regulación del metábolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
MY178160A (en) 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CN106659146B (zh) 2014-05-05 2020-06-23 再生元制药公司 人源化c5和c3动物
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
MX2016015971A (es) 2014-06-03 2017-08-08 Lupin Ltd Proceso de cultivo celular para la producción de una proteína.
BR112017005110A2 (pt) 2014-09-16 2018-01-23 Regeneron Pharma anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
KR20240093910A (ko) 2015-04-01 2024-06-24 베링거 인겔하임 인터내셔날 게엠베하 세포 배양 배지
TWI870789B (zh) * 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR102777500B1 (ko) 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. 최적화된 항-cd3 이중특이적 항체 및 이의 용도
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
TWI734775B (zh) 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基
BR112020000127A2 (pt) 2017-07-06 2020-07-07 Regeneron Pharmaceuticals, Inc. método para selecionar um hidrolisado de soja, e, glicoproteína

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517235A (ja) * 1998-06-08 2002-06-18 ジェネスパン コーポレイション 安定化一過性遺伝子発現
CN101603026A (zh) * 2009-06-19 2009-12-16 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506413A (ja) * 2018-11-02 2022-01-17 ウーシー バイオロジクス アイルランド リミテッド 連続的採取を行い細胞流出を行わない強化灌流による細胞培養法
JP2023109835A (ja) * 2018-11-02 2023-08-08 ウーシー バイオロジクス アイルランド リミテッド 連続的採取を行い細胞流出を行わない強化灌流による細胞培養法
JP7707062B2 (ja) 2018-11-02 2025-07-14 ウーシー バイオロジクス アイルランド リミテッド 連続的採取を行い細胞流出を行わない強化灌流による細胞培養法
JP2022512928A (ja) * 2018-11-07 2022-02-07 リヒター ゲデオン ニュイルヴァーノシャン ミューコェデー レースヴェーニュタールシャシャーグ 細胞培養で生産される組換え糖タンパク質のグリコシル化プロファイルを変更する方法
US12168791B2 (en) 2018-11-07 2024-12-17 Richter Gedeon Nyrt. Method for modifying the glycosylation profile of a recombinant glycoprotein produced in cell culture
JP7855505B2 (ja) 2019-12-06 2026-05-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法

Also Published As

Publication number Publication date
JP7198868B2 (ja) 2023-01-04
IL313856A (en) 2024-08-01
AU2022291430A1 (en) 2023-02-02
CN107922920A (zh) 2018-04-17
IL313856B1 (en) 2025-10-01
TW201718849A (zh) 2017-06-01
IL313856B2 (en) 2026-02-01
KR20240144464A (ko) 2024-10-02
JP2022162157A (ja) 2022-10-21
JP2024098107A (ja) 2024-07-19
CN114854668A (zh) 2022-08-05
IL298775B1 (en) 2025-01-01
EP4442808A2 (en) 2024-10-09
JP7781954B2 (ja) 2025-12-08
US12359166B2 (en) 2025-07-15
JP2024098108A (ja) 2024-07-19
EP4442808A3 (en) 2024-12-25
US20200157492A1 (en) 2020-05-21
IL298775B2 (en) 2025-05-01
CN114854668B (zh) 2025-06-03
AU2022291430B2 (en) 2024-11-14
AU2024204125A1 (en) 2024-07-04
IL313855B2 (en) 2026-04-01
EP4442807A2 (en) 2024-10-09
TWI797060B (zh) 2023-04-01
US20240018467A1 (en) 2024-01-18
CA3236082A1 (en) 2017-02-09
US20240309315A1 (en) 2024-09-19
IL313855B1 (en) 2025-12-01
US10927342B2 (en) 2021-02-23
WO2017024062A1 (en) 2017-02-09
AR105602A1 (es) 2017-10-18
TWI870789B (zh) 2025-01-21
HK1250740A1 (zh) 2019-01-11
US20220235318A1 (en) 2022-07-28
EP3331987A1 (en) 2018-06-13
MY203884A (en) 2024-07-23
CN107922920B (zh) 2022-04-12
TW202340452A (zh) 2023-10-16
MY208943A (en) 2025-06-12
US20240309316A1 (en) 2024-09-19
TWI899515B (zh) 2025-10-01
CA3236085A1 (en) 2017-02-09
KR102709927B1 (ko) 2024-09-26
TW202330904A (zh) 2023-08-01
TW202440903A (zh) 2024-10-16
JP2021112215A (ja) 2021-08-05
MY192561A (en) 2022-08-29
AR132934A2 (es) 2025-08-13
CA2989178C (en) 2025-10-07
MX2022003477A (es) 2022-04-25
US20250340832A1 (en) 2025-11-06
JP7850767B2 (ja) 2026-04-23
KR20180032581A (ko) 2018-03-30
IL323287A (en) 2025-11-01
US12359165B2 (en) 2025-07-15
CA2989178A1 (en) 2017-02-09
US12221619B2 (en) 2025-02-11
EP4442807A3 (en) 2025-01-01
AU2016301305B2 (en) 2022-09-29
TW202440904A (zh) 2024-10-16
KR20240144463A (ko) 2024-10-02
US20250327023A1 (en) 2025-10-23
US11312936B2 (en) 2022-04-26
EA201890137A1 (ru) 2018-07-31
AU2024204127A1 (en) 2024-07-04
IL256525B2 (en) 2023-05-01
AR132933A2 (es) 2025-08-13
HK1248279A1 (zh) 2018-10-12
IL256525A (en) 2018-02-28
IL313855A (en) 2024-08-01
JP7495451B2 (ja) 2024-06-04
US12577528B2 (en) 2026-03-17
BR112018002214A2 (pt) 2018-09-04
IL256525B1 (en) 2023-01-01
MX2018001531A (es) 2018-04-24
US20180223249A1 (en) 2018-08-09
IL298775A (en) 2023-02-01
AU2016301305A1 (en) 2018-01-25
MX390940B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
JP7850767B2 (ja) タウリン補足細胞培養培地およびその使用
HK40116837A (en) Taurine supplemented cell culture medium and methods of use
EA048952B1 (ru) Среда для культивирования клеток с добавлением таурина и способы применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190621

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200811

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210512

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210512

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210520

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210521

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20210526